Pancreatic cancer: Symptoms, causes and treatment aol.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aol.co.uk Daily Mail and Mail on Sunday newspapers.
Professor Andrew Biankin By Kristy Dorsey A freshly-minted spin-out business from the University of Glasgow has signed a licensing agreement with genomic analysis specialist Congenica to create a platform for targeting and tailoring cancer treatment. Set up earlier this year, Gabriel Precision Oncology has developed software designed specifically to examine the genomics of cancer patients. This covers the interpretation of how all an individual’s genes interact with one another to identify their combined influence on that person’s health. Cambridge-based Congenica already has similar technology used in the identification and treatment of rare diseases. Working with Gabriel, the company will expand its genomic interpretation platform to include somatic cancer – cancer caused by genetic mutations, which is the most common cause of the disease.